Dosimetric Evaluation of Permanent Prostate Brachytherapy Using Cs-131 Sources

International Journal of Radiation Oncology Biology Physics

November 1, 2006

Dr. Kurtzman, of San Mateo, California, studied the dosimetry of 58 patients implanted with Cs-131. He noted the dose “inhomogeneity” – as measured by the dosimetric concept “V150” – to be very low as compared to other brachytherapy isotopes.

Is There a Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Isotope?

Authors: DeFoe SG, et al.

Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy

Authors: R.M. Benoit, R.P. Smith, S. Beriwal

Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution

Authors: C.S. Platta, D. Khuntia, J. Adkinson, E. Olson, S. Jennifer, H. Odau, R.R. Patel

Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point

Authors: R. Yaparpalvi, J. Rossinow, W.A. Cavanagh, W. Choi, L. Minsky, N. Kahan, W. Bodner, M. Garg, S. Kalnicki, C. Guha

Patient Information

Clinician Information

Cesium 131 Products

Why Theranostics?

Pipeline

Dosimetric Evaluation of Permanent Prostate Brachytherapy Using Cs-131 Sources

Authors

Related posts

Is There a Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Isotope?

Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy

Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution

Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point

Search

Recent Posts

Archives

Company

Brachytherapy

Theranostics

Newsletter

Email newsletter sign-up

Company

Newsletter

Email newsletter sign-up